Deep learning classification of MRI differentiates brain changes in genetic and idiopathic Parkinson's disease

Megan Courtman,Mark Thurston,Hongrui Wang,Sube Banerjee,Adam Streeter,Lucy McGavin,Stephen Hall,Lingfen Sun,Emmanuel Ifeachor,Stephen Mullin
DOI: https://doi.org/10.1101/2024.11.21.24317644
2024-11-22
Abstract:Background The prospect of neuroprotective treatments for Parkinson's disease highlights the need for early diagnostic tests. Specialised MRI sequences suggest changes related to Parkinson's disease may be detectable. Objectives We used the Parkinson's Progression Markers Initiative dataset to investigate whether deep learning can detect early brain MRI changes of idiopathic and GBA/LRRK2 prodromal Parkinson's disease. Methods Pairs of matched cohorts were used to train convolutional neural networks to classify T2 axial images. Explainability methods were used to visualise drivers of model predictions. Results Models built to distinguish between idiopathic Parkinson's disease scans (n=504) and matched controls exhibited good classification performance for scans taken more than four years after diagnosis, with a Receiver Operating Characteristic area-under-the-curve of 0.89 (n=98). Model performance deteriorated as time since diagnosis reduced. Models built to distinguish non-manifesting carriers of LRRK2 (area-under-the-curve 0.92, 90% accuracy, n=115) and GBA (area-under-the-curve 0.94, 92% accuracy, n=109) from controls exhibited excellent classification performance. All models demonstrated foci of interest in cerebrospinal fluid spaces surrounding the brainstem. Models using GBA scans also identified foci of interest in occipital lobes. Conclusions Deep learning models appear able to reproducibly detect changes in the brains of those with established but not early Parkinson's disease. Conversely changes in at risk genetic cohorts are detectable at all stages, including in those who have not developed Parkinson's disease. This implies a distinct pathological process ongoing within the brains of carriers of Parkinson's disease genetic risk factors compared to those with sporadic Parkinson's disease.
What problem does this paper attempt to address?